Biogen News and Research

RSS
Free education program highlights advancements in treatment of blood cancers, importance of clinical trials

Free education program highlights advancements in treatment of blood cancers, importance of clinical trials

Biogen, Elan launch My MS Health, a web-based PRO research program

Biogen, Elan launch My MS Health, a web-based PRO research program

Biogen Idec to join global MS community to commemorate the second annual World MS Day

Biogen Idec to join global MS community to commemorate the second annual World MS Day

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Phase III PRIMA study data of Rituxan to be featured at 46th ASCO

Phase III PRIMA study data of Rituxan to be featured at 46th ASCO

Roche, Biogen Idec discontinue ocrelizumab clinical development programme for RA

Roche, Biogen Idec discontinue ocrelizumab clinical development programme for RA

Genmab reports revenues of DKK 107M for first-quarter 2010

Genmab reports revenues of DKK 107M for first-quarter 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

Immunogen reports a net loss of $12.1 million in third quarter 2010

Immunogen reports a net loss of $12.1 million in third quarter 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

New syndicated report covers the use of DMAs for treatment of MS published

New syndicated report covers the use of DMAs for treatment of MS published

Elan's first-quarter total revenue up by 27% to $310.5M

Elan's first-quarter total revenue up by 27% to $310.5M

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Study shows beneficial impact of TYSABRI on QoL in MS patients

Study shows beneficial impact of TYSABRI on QoL in MS patients

Study: Atorvastatin may slow down MS progression

Study: Atorvastatin may slow down MS progression

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

Crohn's disease: Remicade prescription to decrease, while Humira's increases

Crohn's disease: Remicade prescription to decrease, while Humira's increases

Physicians increase prescription of new biologics

Physicians increase prescription of new biologics